Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

HUTCHMED (China) (0013) Stock Price & Analysis

8 Followers

0013 Stock Chart & Stats

HK$24.28HK$0.22(4.84%)
At close: 4:00 PM GMT+8
HK$20HK$22HK$24Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 24.00 - HKD 24.48
52-Week Range
HKD 15.57 - HKD 25.58
Previous Close
HKD 23.16
Volume
N/A
Average Volume (3M)
4.21M
Market Cap
HKD 21.18B
Enterprise Value
HKD 4.72B
Total Cash (Recent Filing)
HKD 1.38B
Total Debt (Recent Filing)
HKD 94.51M
Price to Earnings (P/E)
167.3
Beta
0.89
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
0.31
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Very low leverage gives HUTCHMED financial flexibility while it funds research, development, and commercialization. A sizable equity base can help the company withstand operating volatility and pursue opportunities without relying heavily on borrowing or facing substantial interest burdens.

Current Positive Cash Generation

Positive trailing-twelve-month operating and free cash flow indicates that the business is currently generating internal funding, despite historical volatility. If maintained, this can support ongoing development and commercialization activities while reducing dependence on external capital.

Targeted Oncology Platform

HUTCHMED operates in specialized targeted therapies and immunotherapies, areas that can support differentiated products and long-term market opportunities. Its ability to work with global pharmaceutical partners also broadens commercialization reach and may support portfolio development.

Bears Say

Weak Revenue Trend

Revenue declines across recent annual periods indicate inconsistent commercial momentum rather than a steadily expanding base. Continued weakness could limit operating leverage, reduce resources available for development, and make future profitability more dependent on successful product launches.

Negative Core Profitability

Negative EBIT and EBITDA margins show that the core business is not yet producing sustainable operating profits. The low gross margin further limits the cushion available to absorb research, commercialization, and other operating costs, making earnings improvement dependent on stronger economics.

Volatile Cash Flow

Cash generation has reversed materially from strong 2023 levels, with negative operating and free cash flow in 2025 and sharply declining free cash flow growth. This volatility weakens confidence in self-funding capacity and could constrain investment through operating cycles.

HUTCHMED (China) News

0013 FAQ

What was HUTCHMED (China) ’s price range in the past 12 months?
HUTCHMED (China) lowest stock price was HK$15.57 and its highest was HK$25.58 in the past 12 months.
What is HUTCHMED (China) ’s market cap?
HUTCHMED (China) ’s market cap is HK$21.18B.
When is HUTCHMED (China) ’s upcoming earnings report date?
HUTCHMED (China) ’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 112 days.
How were HUTCHMED (China) ’s earnings last quarter?
HUTCHMED (China) released its earnings results on Jul 30, 2026. The company reported HK$0.157 earnings per share for the quarter, missing the consensus estimate of HK$0.228 by -HK$0.071.
Is HUTCHMED (China) overvalued?
According to Wall Street analysts HUTCHMED (China) ’s price is currently Undervalued.
Does HUTCHMED (China) pay dividends?
HUTCHMED (China) does not currently pay dividends.
What is HUTCHMED (China) ’s EPS estimate?
HUTCHMED (China) ’s EPS estimate is 0.31.
How many shares outstanding does HUTCHMED (China) have?
HUTCHMED (China) has 872,335,140 shares outstanding.
What happened to HUTCHMED (China) ’s price movement after its last earnings report?
HUTCHMED (China) reported an EPS of HK$0.157 in its last earnings report, missing expectations of HK$0.228. Following the earnings report the stock price went down -0.056%.
Which hedge fund is a major shareholder of HUTCHMED (China) ?
Currently, no hedge funds are holding shares in HK:0013
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology